Table 2. Incidence rate ratios for intervention effects in access rates to TB diagnostic and treatment services over the 23 months of the intervention.
Incidence rate ratio (95% CI)1 | P value | Incidence rate ratio (95% CI)1 | P value | |
---|---|---|---|---|
The first 12 months of the trial | TB testing | TB treatment initiation | ||
Overall effect (unadjusted) | 1.042 (0.860–1.262 | 0.676 | 0.824 (0.513–1,324) | 0.676 |
Overall effect (adjusted) | 1.152 (1.009–1.359) | 0.003 | 1.18 (0.903–1.533) | 0.114 |
Covariates: | ||||
Intervention Arm2 | 1.215 (1.071, 1.379) | 0.003 | 1.204 (0.957, 1.515) | 0.112 |
Baseline rate3 | 1.004 (1.004, 1.004) | 0.000 | 1.025 (1.003, 1.048) | 0.025 |
Month4 | 0.940 (0.906, 0.975) | 0.001 | 1.004 (0.978, 1.031) | 0.748 |
Gender | 0.028 (0.028, 0.029) | 0.000 | 1.255 (0.306, 5.140) | 0.752 |
Interaction between trial arm and month5 | 0.948 (0.913, 0.986) | 0.013 | 0.981 (0.944, 1.012) | 0.335 |
Number of testing or treatment sites6 | 0.920 (0.919, 0.921) | 0.000 | 1.247 (1.096, 1.419) | 0.001 |
The last 11 months of the trial | ||||
Overall effect (unadjusted) | 1.016 (0.812–1.271) | 0.892 | 0.758 (0.445–1.290) | 0.308 |
Overall effect (adjusted) | 0.659 (0.441–0.983) | 0.023 | 0.552 (0.397–0.767) | <0.001 |
Covariates: | ||||
Intervention Arm2 | 0.648 (0.445,0.943) | 0.023 | 0.529 (0.387, 0.722) | <0.001 |
Baseline rate3 | 0.993 (0.988,0.998) | 0.008 | 1.038 (1.021, 1.054) | <0.001 |
Month4 | 0.963 (0.959,0.967) | 0.002 | 0.974 (0.959, 0.989) | 0.001 |
Gender | 6.997 (2.421,20.231) | <0.001 | 0.320 (0.117, 0.874) | 0.026 |
Interaction between trial arm and month5 | 1.017 (0.992, 1.043) | 0.180 | 1.044 (1.027, 1.062) | <0.001 |
Number of testing or treatment sites6 | 1.119 (0.757,0.876) | <0.001 | 1.269 (1.155, 1.395) | <0.001 |
1Incidence Rate Ratio (IRR) = rate in Early arm/rate in Delayed arm
2Intervention status (Early/Delayed)
3Baseline testing or treatment initiation rates
4Month of observation
5interaction between intervention status and measurement time
6number of testing or treatment sites.